Skip to content

Efficacy of Two Nasal Products for Decongestion and Mucus Fluidification

Clinical Evaluation of the Efficacy of Two Nasal Products for Decongestion and Mucus Fluidification

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04230993
Acronym
DEFI
Enrollment
210
Registered
2020-01-18
Start date
2019-12-24
Completion date
2020-06-20
Last updated
2020-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rhinitis

Brief summary

The main objective is to compare the effect of nasal washing on nasal discharge and nasal congestion during treatment after 3 days of use.

Detailed description

The main endpoint is a symptom score derived from the Jackson scale: sum of 2 items relating to runny nose and nasal congestion (stuffy nose), with ratings of 0 to 3 for each (0: absent ; 1: mild; 2: moderate; 3: severe).

Interventions

OTHERSea water solution

Administration of different sea water solution is performed and the rating of cold symptoms according to the Jackson scale, the fluidity of mucus and the ease of blowing will be evaluated.

Sponsors

YSLab
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
3 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Person with an upper respiratory condition (cold, rhinitis, nasopharyngitis ...) with symptoms of nasal congestion and intense runny nose moderate to severe (Jackson derived score ≥ 4) * Ability of the patient (for adults) or their legal representative (for children) to follow the guidelines of the medical device * have given their written informed consent

Exclusion criteria

* Patient with no cold symptoms, including no nasal congestion (chronic dry rhinitis…) * Patient under treatment with cortisone derivative, mucolytic, or medication containing pseudoephedrine or related product acting on nasal congestion or having used such a product in the 3 days before inclusion * Patient who used a nasal wash product in the 3 days before inclusion * Patient allergic to seafood, or to any of the components of the products under study * Vulnerable patient whose inclusion is not justified by the research objectives: woman pregnant, parturient, psychiatric patient, or adult subject to legal protection * Patient participating or having participated in any other clinical study in the 30 days before the study.

Design outcomes

Primary

MeasureTime frameDescription
Effect of nasal washing with a hypertonic seawater solution Nose hygiene).3 daysEffect of nasal washing with a hypertonic seawater solution (Ocean Bio Actif-Fluid + or Ocean Bio Actif-Stuffy nose) on runny nose and nasal congestion during treatment after 3 days of use, compared to an isotonic solution (Ocean Bio Actif- Nose hygiene). symptom score (runny nose and nasal congestion) derived from the Jackson scale with a score of 0 to 3 for each (0: absent; 1: mild; 2: moderate; 3: severe) between Day 0 and Day 3.

Secondary

MeasureTime frameDescription
Presence or absence of fluid mucus7 daysThe effect of nasal wash on the evolution of the mucus fluidification over time
Global Clinical Impression Scalebetween day 3 and day 7Global Clinical Impression of the investigator on the evolution of symptoms
Global Patient Impression Scalebetween day 3 and day 7Global Impression of the patient on the evolution of symptoms
Symptom score7 daysThe effect of nasal wash on the evolution of symptoms over time
Safety of medical device7 daysNumber of adverse events
Likert scale7 daysSatisfaction of patient for the medical device
Number of concomitant treatment7 daysconcomitant administration of treatments related to rhinitis
Use of medical device7 daysNumber of daily sprays

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026